Study sponsor: Praxis Precision Medicines
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Estimated
Actual
2025-09
2025-10-10
Enrolling by invitation
Active not recruiting
measure: Parallel Design: Change from Baseline (CFB) to Week 12 (Day 84) on mADL11; measure: Randomized Withdrawal: The proportion of participants that maintain response, as defined by change in mADL11 score, following randomized withdrawal; measure: Long-term Safety Study: Number of participants with Adverse Events (AE) and their severity.
measure: Parallel Design: Change from Baseline (CFB) to Week 8 (Day 56) on mADL11 score; measure: Randomized Withdrawal: The proportion of participants that maintain response, as defined by change in mADL11 score, following randomized withdrawal; measure: Long-term Safety Study: Number of participants with Adverse Events (AE) and their severity.
The saved outcome text may be shortened. Check the source for full wording.
count: 600; type: ESTIMATED
count: 1000; type: ESTIMATED
2024-09
2025-09
Recruiting
Enrolling by invitation
Trial